Answers are grounded in this paper and cite their sources.
During the coronavirus disease 2019 (COVID-19) pandemic, many patients with rheumatoid arthritis (RA) were switched from intravenous (IV) to subcutaneous (SC) biologic therapies to reduce hospital visits. Although comparable efficacy between the 2 routes has been reported for abatacept and tocilizumab,1-4 real-world data on patient experience following an externally imposed treatment transition remain limited.
No takes yet. Share an insight, caveat, or question.
Wirth et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: